SUBSCRIBERS
Samsung's drug-making unit soars on market debut
Published Thu, Nov 10, 2016 · 09:50 PM
Seoul
SHARES in Samsung's drug-making unit soared almost six per cent on their market debut on Thursday, after one of South Korea's biggest ever initial public offerings that raised nearly US$2 billion.
Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 per cent from its IPO price to close at 144,000 won (S$174) in Seoul, putting its total value at about 9.5 trillion won.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue